| ding, yanhua |
NCT04440696: To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder |
|
|
| Recruiting | 1/2 | 48 | RoW | Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG, Placebo | Grand Life Science (Liaoning) Co., Ltd., The First Hospital of Jilin University | Hyperphosphatemia | 06/22 | 12/22 | | |
NCT06778850: A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants |
|
|
| Recruiting | 1/2 | 131 | RoW | MDR-001, palcebo | MindRank AI Ltd | Overweight and Obese Volunteers | 07/25 | 12/25 | | |
NCT04536532: Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study |
|
|
| Terminated | 1/2 | 52 | RoW | HEC121120 tablets, HEC121120 placebo tablets, entecavir tablets, entecavir placebo tablets | Sunshine Lake Pharma Co., Ltd. | Hepatitis B, Chronic | 03/23 | 03/23 | | |
NCT05828745: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B |
|
|
| Recruiting | 1/2 | 40 | RoW | CB06-036, Placebo | Shanghai Zhimeng Biopharma, Inc. | Chronic Hepatitis b | 12/24 | 12/25 | | |
NCT06115993: A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients |
|
|
| Active, not recruiting | 1/2 | 270 | RoW | AHB-137 injection, Placebo | Ausper Biopharma Co., Ltd. | Hepatitis B, Chronic | 12/24 | 01/26 | | |
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B |
|
|
| Not yet recruiting | 1/2 | 162 | RoW | TQA3038 injection/placebo, Nucleotide drugs Control group | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B, Chronic | 09/26 | 09/26 | | |
| Not yet recruiting | 1/2 | 40 | NA | XKH001 Injection, XKH001, XKH001 Placebo Injection, XKH001 Placebo | Beijing Kanova Biopharmaceutical Co., LTD | Asthma | 08/24 | 12/24 | | |
NCT06048588: YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis |
|
|
| Recruiting | 1/2 | 130 | RoW | YN001, Placebo for YN001, Placebo, rosuvastatin calcium tablets, Crestor® | Beijing Inno Medicine Co., Ltd. | Atherosclerotic Cardiovascular Disease | 12/24 | 04/25 | | |
| Recruiting | 1/2 | 100 | RoW | WX390, WXFL10030390, Toripalimab | Shanghai Jiatan Pharmatech Co., Ltd | Solid Tumor | 11/25 | 11/25 | | |
NCT06190340: A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects |
|
|
| Completed | 1 | 40 | RoW | TNP-2092 capsules, Rifaquizinone capsules, Placebo, TNP-2092 placebo capsules | TenNor Therapeutics (Suzhou) Limited, The First Hospital of Jilin University | Helicobacter Pylori Infection | 09/17 | 09/17 | | |
NCT05162053: PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers |
|
|
| Completed | 1 | 128 | US, RoW | vicagrel Capsules, Clopidogrel Tablets, PLAVIX | Jiangsu vcare pharmaceutical technology co., LTD | Acute Coronary Syndrome | 11/22 | 11/22 | | |
NCT05668897: Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG171 Tablets |
|
|
| Completed | 1 | 78 | RoW | GST-HG171, placebo of GST-HG171 | Fujian Akeylink Biotechnology Co., Ltd. | COVID-19 | 12/22 | 12/22 | | |
NCT05492630: Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects |
|
|
| Completed | 1 | 138 | RoW | HEC73077 tablets, HEC73077 placebo tablets | Sunshine Lake Pharma Co., Ltd. | Diabetic Nephropathy | 01/23 | 01/23 | | |
NCT05391360: Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study |
|
|
| Completed | 1 | 128 | RoW | Freethiadine tablets(part I), Freethiadine tablets (part II), Freethiadine placebo tablets, entecavir tablets | Sunshine Lake Pharma Co., Ltd. | Hepatitis B, Chronic | 01/23 | 01/23 | | |
NCT05057949: A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants |
|
|
| Active, not recruiting | 1 | 32 | RoW | Larotinib, Z650, Rifampin, Rifampin Capsules, Itraconazole, Itraconazole Capsules | Sunshine Lake Pharma Co., Ltd. | Healthy Volunteers | 01/23 | 03/23 | | |
NCT05943886: A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects |
|
|
| Completed | 1 | 164 | RoW | HEC88473 injection, Placebo | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Healthy Subjects, Obesity, T2DM (Type 2 Diabetes Mellitus) | 02/23 | 02/23 | | |
NCT04711343: Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects |
|
|
| Completed | 1 | 216 | RoW | BAT2306, Cosentyx (US-licensed), Secukinumab, Cosentyx (EU-licensed) | Bio-Thera Solutions | Psoriasis | 05/23 | 06/23 | | |
NCT06143423: A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects. |
|
|
| Recruiting | 1 | 74 | RoW | AP026 (TQA2226) for injection, AP026 (TQA2226) for injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Diabetes Mellitus, Type 2 | 06/24 | 12/24 | | |
NCT05576454: Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 207 | RoW | Mepolizumab Injection (BAT2606 Injection), BAT2606 Injection, Mepolizumab Injection (EU-licensed Nucala), EU-licensed Nucala, Mepolizumab Injection (US-licensed Nucala), US-licensed Nucala | Bio-Thera Solutions | Severe Asthma | 05/23 | 06/23 | | |
NCT05332730: A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi® |
|
|
| Completed | 1 | 375 | RoW | BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product) | Bio-Thera Solutions, The First Hospital of Jilin University | Psoriatic Arthritis | 06/23 | 07/23 | | |
NCT06620731: Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency |
|
|
| Completed | 1 | 24 | RoW | FCN-437c capsule | Ahon Pharmaceutical Co., Ltd. | Hepatic Insufficiency | 09/23 | 09/23 | | |
NCT05874622: A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis. |
|
|
| Completed | 1 | 30 | RoW | VC005 tablets, VC005 Tablets Placebo | Jiangsu vcare pharmaceutical technology co., LTD | Rheumatoid Arthritis | 10/23 | 10/23 | | |
NCT06176716: Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride |
|
|
| Recruiting | 1 | 24 | RoW | ET-26 | Ahon Pharmaceutical Co., Ltd. | Hepatic Insufficiency | 03/24 | 04/24 | | |
NCT06173011: A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults |
|
|
| Recruiting | 1 | 168 | RoW | QL2107, Keytruda®(china), Keytruda®(US) | Qilu Pharmaceutical Co., Ltd. | Tumor | 07/24 | 07/24 | | |
NCT05576584: Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG121 Tablets |
|
|
| Recruiting | 1 | 114 | RoW | GST-HG121 tablets, Placebo | Fujian Akeylink Biotechnology Co., Ltd., The First Hospital of Jilin University | Pharmacokinetics, Food Affect, Single Ascending Dose, Maximum Applicable Dose | 12/23 | 03/24 | | |
| Recruiting | 1 | 15 | RoW | SynOV1.1 | Beijing Syngentech Co., Ltd. | Hepatocellular Carcinoma | 12/23 | 06/24 | | |
NCT06080555: Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia |
|
|
| Completed | 1 | 84 | RoW | Ferric Carboxymaltose Injection, Ferric Carboxymaltose Injection [Ferinject] | Sichuan Huiyu Pharmaceutical Co., Ltd, The First Hospital of Jilin University, Suzhou Guochen Biotek Co., Ltd., Boji Data Technology (Beijing) Co., Ltd., Boji Medical Technology Co., Ltd. | Iron Deficiency, Anaemia | 01/24 | 03/24 | | |
NCT06310746: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects |
|
|
| Recruiting | 1 | 66 | RoW | GARP/TGF-β1 monoclonal antibody, Placebo | Shanghai Henlius Biotech | IPF | 12/25 | 12/26 | | |
| Active, not recruiting | 1 | 35 | RoW | XKH001 Injection, XKH001, XKH001Placebo Injection, XKH001Placebo | Beijing Kanova Biopharmaceutical Co., LTD | Healthy Adults | 10/24 | 12/24 | | |
| Recruiting | 1 | 216 | RoW | BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/25 | | |
NCT06694948: A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects |
|
|
| Active, not recruiting | 1 | 26 | RoW | pimicotinib capsules | Abbisko Therapeutics Co, Ltd | Pharmacokinetics | 05/25 | 05/25 | | |
| Recruiting | N/A | 32 | RoW | GST-HG171 Tablets | Fujian Akeylink Biotechnology Co., Ltd. | COVID-19 Pneumonia | 02/24 | 03/24 | | |
